Xgeva (Denosumab) for Myeloma

Overview
Xgeva is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to prevent fractures and spinal cord compression in people whose bones have been weakened by multiple myeloma. Xgeva is also known by its drug name, denosumab.

Xgeva is a member of a class of drugs called biologics. Xgeva is a monoclonal antibody that is believed to work by preventing the breakdown of bones.

How do I take it?
Xgeva is administered as a subcutaneous injection once every four weeks.

Doctors often recommend taking calcium and vitamin D supplements while undergoing treatment with Xgeva.

Side effects
The FDA-approved label for Xgeva lists common side effects including headache, fatigue, back pain, swelling in the extremities, nausea, diarrhea, and anemia.

Rare but serious side effects listed for Xgeva include low calcium levels, osteonecrosis (death of bone tissue) in the jaw, atypical femoral (upper leg) fractures, hypersensitivity reactions, and fetal harm in pregnant women. Some people have a higher risk for vertebral (spinal) fractures after discontinuing Xgeva.

For more details about this treatment, visit:

Xgeva — Amgen
https://www.xgeva.com

Drug Therapy for Multiple Myeloma — American Cancer Society
https://www.cancer.org/cancer/multiple-myeloma/...